Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. (Q50582729)

16 March 2018

title

Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C. (English)

1 reference

16 March 2018

1 reference

1

1 reference

16 March 2018

Thomas Berg

2

1 reference

16 March 2018

Tilman Sauerbruch

10

object named as

Tilman Sauerbruch

1 reference

16 March 2018

Ulrich Spengler

11

object named as

Ulrich Spengler

1 reference

16 March 2018

author name string

Rainer P Woitas

3

1 reference

16 March 2018

Frank Grünhage

4

1 reference

16 March 2018

Agathe Iwan

5

1 reference

16 March 2018

Lothar Hess

6

1 reference

16 March 2018

Hans H Brackmann

7

1 reference

16 March 2018

Bernd Kupfer

8

1 reference

16 March 2018

Andrea Schernick

9

1 reference

16 March 2018

publication date

1 August 2003

1 reference

16 March 2018

published in

Journal of Hepatology

1 reference

16 March 2018

volume

39

1 reference

16 March 2018

issue

2

1 reference

16 March 2018

page(s)

245-252

1 reference

16 March 2018

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

CCR5 is characteristic of Th1 lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Association of rheumatoid arthritis with a functional chemokine receptor, CCR5

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

CC chemokine receptor 5 and renal-transplant survival

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Association of CCR5 ▵32 with reduced risk of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Delta 32 deletion of CCR5 gene and association with asthma or atopy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

An immunoassay for specific amplified HCV sequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the inte

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

1 reference

7 January 2021

Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900193-4

7 January 2021

10.1016/S0168-8278(03)00193-4

Identifiers

DOI

1 reference

16 March 2018

release_tpvo6eekqrffpaohg4dprxlzsm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tpvo6eekqrffpaohg4dprxlzsm

24 November 2022

mapped directly with Wikidata item

1 reference

16 March 2018